title: Effectiveness and complications of anthracycline and taxane in the therapy of breast cancer: a meta-analysis.
abstract: OBJECTIVE
  To compare the efficacy and safety between anthracycline & taxane and anthracycline in the treatment of breast cancer.
  
  
  METHODS
  Computer-assisted literature search was performed with PubMed, MEDLINE, EMBASE and Cochrane Controlled Trials Register (CCTR) to identify pertinent literatures. Software RevMan 5.0 was used for statistical analysis. The measurement of interest outcomes included severe neurotoxicity, death without breast cancer recurrences, leukemia, venous thrombus and severe cardiotoxicity.
  
  
  RESULTS
  A total of 10 randomized controlled trial studies (RCTs) containing 18,198 cases were selected in this meta-analysis. Of which, 9,902 cases were treated with anthracycline & taxane and 8,296 cases treated with anthracycline alone as control. Anthracycline & taxane showed lower risks of incident leukemia (RR = 0.40; 95% CI: 0.18, 0.90), venous thrombus (RR = 0.49; 95% CI: 0.29, 0.84) and severe cardiotoxicity (RR = 0.41, 95%CI: 0.26, 0.66), but higher risks of incident severe neurotoxicity (RR = 5.97; 95% CI: 1.72, 20.65) and non-recurrent death (RR = 1.79; 95% CI: 1.06, 3.04), compared to anthracycline alone.
  
  
  CONCLUSIONS
  Clinically important differences exist for general safety in favour of the anthracycline & taxane rather than anthracycline alone. However, as a result of tumor recurrent rate, anthracycline might be superior to anthracycline & taxane. A longer duration of follow-up and a larger number of cases are required to better assess the efficacy and safety profile of the treatment of breast cancer.
authors: Department of Breast Surgery, Yiwu Maternity and Child Care Hospital, Yiwu, 322000, China.
authors: Qing-jing
authors: QJ
authors: Feng
authors: Feng
authors: F
authors: Zhang
authors: Xiao-yun
authors: XY
authors: Huang
authors: Zhi-xiang
authors: ZX
authors: Wu
mesh_terms: D018943:Anthracyclines / Q000009:adverse effects* / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D001952:Bridged-Ring Compounds / Q000009:adverse effects* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D043823:Taxoids / Q000009:adverse effects* / Q000627:therapeutic use*
chemical_list: D018943:Anthracyclines; D000970:Antineoplastic Agents; D001952:Bridged-Ring Compounds; D043823:Taxoids; C080625:taxane
references: J Clin Oncol. 2006 Dec 1;24(34):5381-7
references: 17135639
references: Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8
references: 12629218
references: J Clin Oncol. 2006 Aug 10;24(23):3726-34
references: 16720680
references: J Natl Cancer Inst. 2008 Jun 4;100(11):805-14
references: 18505968
references: J Clin Oncol. 2006 Dec 20;24(36):5664-71
references: 17116941
references: Proc Natl Acad Sci U S A. 2008 Jul 1;105(26):9053-8
references: 18574145
references: Am J Health Syst Pharm. 2008 May 15;65(10 Suppl 3):S4-9
references: 18463331
references: Oncology. 2010;78(3-4):274-81
references: 20530973
references: J Clin Oncol. 2008 Jan 1;26(1):44-53
references: 18165639
references: Lancet Oncol. 2005 Nov;6(11):886-98
references: 16257797
references: J Natl Cancer Inst. 2008 Jan 16;100(2):121-33
references: 18182617
references: Breast. 2005 Dec;14(6):576-81
references: 16199160
references: J Clin Oncol. 2010 Jan 1;28(1):77-82
references: 19901117
references: Breast Cancer Res Treat. 2010 Jan;119(1):95-104
references: 19636702
references: Lancet. 2009 May 16;373(9676):1681-92
references: 19447249
references: N Engl J Med. 2010 Dec 2;363(23):2200-10
references: 21121833
references: Chem Biol Interact. 2002 Mar 20;139(3):283-99
references: 11879817
references: J Clin Oncol. 2006 Apr 20;24(12):1940-9
references: 16622270
references: J Clin Oncol. 2009 May 20;27(15):2474-81
references: 19332727
references: Cancer. 2005 Feb 15;103(4):672-9
references: 15637696
references: J Clin Oncol. 2008 Sep 1;26(25):4092-9
references: 18678836
references: J Protein Chem. 1996 May;15(4):377-88
references: 8819014
references: Am J Pathol. 2000 Mar;156(3):839-47
references: 10702400
references: CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
references: 17237035
references: Cancer. 2006 Jun 1;106(11):2337-44
references: 16649217
references: J Clin Epidemiol. 2000 May;53(5):451-8
references: 10812316